Rebecca L. Olin, MD, MSCE, associate professor in the Department of Medicine at the University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, discusses changes in acute myeloid leukemia (AML) standards of care. In the past, clinicians and researchers have focused their attention on FLT-3 inhibitors, which are often used in combination with chemotherapy or as second-line treatments. Dr. Olin talks about emerging treatments for older patients, like oral azacitidine for maintenance after chemotherapy and venetoclax in place of chemotherapy for borderline patients. For the future, Dr. Olin looks to the promise of IDH1/2 inhibitors for the treatment of AML.
Learn more by clicking here.